Tug of war in the haematopoietic stem cell niche: Do myeloma plasma cells compete for the HSC niche?

Blood Cancer Journal

Volumn 2, Issue 9, 2012, Pages

  Noll, J E ^a   Williams, S A ^a   Purton, L E ^b,c   Zannettino, A C W ^a,d  

^a Bone and Cancer Research Laboratories   (Australia)

^b ST VINCENT'S INSTITUTE OF MEDICAL RESEARCH   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

bone microenvironment; haematopoietic stem cells; myeloma; niche

Indexed keywords

WNT PROTEIN;

BONE REMODELING; CANCER GROWTH; CARCINOGENESIS; CELL DIFFERENTIATION; CELL GROWTH; CELL INTERACTION; CELL LINEAGE; CELL POPULATION; CELL RENEWAL; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL; HUMAN; HYPOXIA; MESENCHYMAL STEM CELL; MICROENVIRONMENT; MULTIPLE MYELOMA; MYELOMA CELL; NONHUMAN; OSTEOBLAST; PLASMA CELL; REVIEW; SIGNAL TRANSDUCTION; STEM CELL NICHE; STROMA CELL;

EID: 84871072957     PISSN: None     EISSN: 20445385     Source Type: Journal    
DOI: 10.1038/bcj.2012.38     Document Type: Review

References (165)

1. Kopp HG, Avecilla ST, Hooper AT, Rafii S. The bone marrow vascular niche: home of HSC differentiation and mobilization. Physiology 2005; 20: 349-356.
2. Krause DS. Regulation of hematopoietic stem cell fate. Oncogene 2002; 21: 3262-3269.
3. Kuehl WM, Bergsagel PL. Multiple myeloma: evolving genetic events and host interactions. Nat Rev Cancer 2002; 2: 175-187.
4. Purton LE, Scadden DT. The Hematopoietic Stem Cell Niche. Stem Book: Cambridge (MA), 2008.
5. Schofield R. The relationship between the spleen colony-forming cell and the haemopoietic stem cell. Blood Cells 1978; 4: 7-25.
6. Calvi LM, Adams GB, Weibrecht KW, Weber JM, Olson DP, Knight MC et al. Osteoblastic cells regulate the haematopoietic stem cell niche. Nature 2003; 425: 841-846.
7. Zhang J, Niu C, Ye L, Huang H, He X, Tong WG et al. Identification of the haematopoietic stem cell niche and control of the niche size. Nature 2003; 425: 836-841.
8. Kiel MJ, Yilmaz OH, Iwashita T, Terhorst C, Morrison SJ. SLAM family receptors distinguish hematopoietic stem and progenitor cells and reveal endothelial niches for stem cells. Cell 2005; 121: 1109-1121.
9. Shackney SE, Ford SS, Wittig AB. Kinetic-microarchitectural correlations in the bone marrow of the mouse. Cell Tissue Kinet 1975; 8: 505-516.
10. Xie Y, Yin T, Wiegraebe W, He XC, Miller D, Stark D et al. Detection of functional haematopoietic stem cell niche using real-time imaging. Nature 2009; 457: 97-101.
11. Grassinger J, Haylock DN, Williams B, Olsen GH, Nilsson SK. Phenotypically identical hemopoietic stem cells isolated from different regions of bone marrow have different biologic potential. Blood 2010; 116: 3185-3196.
12. Benveniste P, Cantin C, Hyam D, Iscove NN. Hematopoietic stem cells engraft in mice with absolute efficiency. Nat Immunol 2003; 4: 708-713.
13. Matsuzaki Y, Kinjo K, Mulligan RC, Okano H. Unexpectedly efficient homing capacity of purified murine hematopoietic stem cells. Immunity 2004; 20: 87-93.
14. Ding L, Saunders TL, Enikolopov G, Morrison SJ. Endothelial and perivascular cells maintain haematopoietic stem cells. Nature 2012; 481: 457-462.
15. Mendez-Ferrer S, Michurina TV, Ferraro F, Mazloom AR, Macarthur BD, Lira SA et al. Mesenchymal and haematopoietic stem cells form a unique bone marrow niche. Nature 2010; 466: 829-834.
16. Omatsu Y, Sugiyama T, Kohara H, Kondoh G, Fujii N, Kohno K et al. The essential functions of adipo-osteogenic progenitors as the hematopoietic stem and progenitor cell niche. Immunity 2010; 33: 387-399.
17. Sugiyama T, Kohara H, Noda M, Nagasawa T. Maintenance of the hematopoietic stem cell pool by CXCL12-CXCR4 chemokine signaling in bone marrow stromal cell niches. Immunity 2006; 25: 977-988.
18. Burger JA, Ghia P, Rosenwald A, Caligaris-Cappio F. The microenvironment in mature B-cell malignancies: a target for new treatment strategies. Blood 2009; 114: 3367-3375.
19. Weiss BM, Abadie J, Verma P, Howard RS, Kuehl WM. A monoclonal gammopathy precedes multiple myeloma in most patients. Blood 2009; 113: 5418-5422.
20. Sirohi B, Powles R. Epidemiology and outcomes research for MGUS, myeloma and amyloidosis. Eur J Cancer 2006; 42: 1671-1683.
21. Heider U, Hofbauer LC, Zavrski I, Kaiser M, Jakob C, Sezer O. Novel aspects of osteoclast activation and osteoblast inhibition in myeloma bone disease. Biochem Biophys Res Commun 2005; 338: 687-693.
22. Nagasawa T. Microenvironmental niches in the bone marrow required for B-cell development. Nat Rev Immunol 2006; 6: 107-116.
23. Cyster JG. Homing of antibody secreting cells. Immunol Rev 2003; 194: 48-60.
24. Harwood NE, Batista FD. New insights into the early molecular events underlying B cell activation. Immunity 2008; 28: 609-619.
25. LeBien TW, Tedder TF. B lymphocytes: how they develop and function. Blood 2008; 112: 1570-1580.
26. Tokoyoda K, Egawa T, Sugiyama T, Choi BI, Nagasawa T. Cellular niches controlling B lymphocyte behavior within bone marrow during development. Immunity 2004; 20: 707-718.
27. Egawa T, Kawabata K, Kawamoto H, Amada K, Okamoto R, Fujii N et al. The earliest stages of B cell development require a chemokine stromal cell-derived factor/pre-B cell growth-stimulating factor. Immunity 2001; 15: 323-334.
28. Ma Q, Jones D, Springer TA. The chemokine receptor CXCR4 is required for the retention of B lineage and granulocytic precursors within the bone marrow microenvironment. Immunity 1999; 10: 463-471.
29. Nagasawa T, Hirota S, Tachibana K, Takakura N, Nishikawa S, Kitamura Y et al. Defects of B-cell lymphopoiesis and bone-marrow myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1. Nature 1996; 382: 635-638.
30. Nagasawa T, Kikutani H, Kishimoto T. Molecular cloning and structure of a pre-Bcell growth-stimulating factor. Proc Nat Acad Sci Usa 1994; 91: 2305-2309.
31. Calame KL. Plasma cells: finding new light at the end of B cell development. Nat Immunol 2001; 2: 1103-1108.
32. Hargreaves DC, Hyman PL, Lu TT, Ngo VN, Bidgol A, Suzuki G et al. A coordinated change in chemokine responsiveness guides plasma cell movements. J Exp Med 2001; 194: 45-56.
33. Ikebuchi K, Wong GG, Clark SC, Ihle JN, Hirai Y, Ogawa M. Interleukin 6 enhancement of interleukin 3-dependent proliferation of multipotential hemopoietic progenitors. Proc Nat Acad Sci USA 1987; 84: 9035-9039.
34. Okano A, Suzuki C, Takatsuki F, Akiyama Y, Koike K, Nakahata T et al. Effects of interleukin-6 on hematopoiesis in bone marrow-transplanted mice. Transplantation 1989; 47: 738-740.
35. Patchen ML, MacVittie TJ, Williams JL, Schwartz GN, Souza LM. Administration of interleukin-6 stimulates multilineage hematopoiesis and accelerates recovery from radiation-induced hematopoietic depression. Blood 1991; 77: 472-480.
36. Gado K, Domjan G, Hegyesi H, Falus A. Role of INTERLEUKIN-6 in the pathogenesis of multiple myeloma. Cell Biol Int 2000; 24: 195-209.
37. Hirano T, Yasukawa K, Harada H, Taga T, Watanabe Y, Matsuda T et al. Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin. Nature 1986; 324: 73-76.
38. Kawano MM, Mihara K, Huang N, Tsujimoto T, Kuramoto A. Differentiation of early plasma cells on bone marrow stromal cells requires interleukin-6 for escaping from apoptosis. Blood 1995; 85: 487-494.
39. Muraguchi A, Kishimoto T, Miki Y, Kuritani T, Kaieda T, Yoshizaki K et al. T cellreplacing factor- (TRF) induced IgG secretion in a human B blastoid cell line and demonstration of acceptors for TRF. J Immunol 1981; 127: 412-416.
40. Degrassi A, Hilbert DM, Rudikoff S, Anderson AO, Potter M, Coon HG. In vitro culture of primary plasmacytomas requires stromal cell feeder layers. Proc Nat Acad Sci USA 1993; 90: 2060-2064.
41. Hao M, Zhang L, An G, Meng H, Han Y, Xie Z et al. Bone marrow stromal cells protect myeloma cells from bortezomib induced apoptosis by suppressing microRNA-15a expression. Leuk Lymphoma 2011; 52: 1787-1794.
42. Nefedova Y, Landowski TH, Dalton WS. Bone marrow stromal-derived soluble factors and direct cell contact contribute to de novo drug resistance of myeloma cells by distinct mechanisms. Leukemia 2003; 17: 1175-1182.
43. Perez LE, Parquet N, Shain K, Nimmanapalli R, Alsina M, Anasetti C et al. Bone marrow stroma confers resistance to Apo2 ligand/TRAIL in multiple myeloma in part by regulating c-FLIP. J Immunol 2008; 180: 1545-1555.
44. Fowler JA, Mundy GR, Lwin ST, Edwards CM. Bone marrow stromal cells create a permissive microenvironment for myeloma development: a new stromal role for Wnt inhibitor Dkk1. Cancer Res 2012; 72: 2183-2189.
45. Gupta D, Treon SP, Shima Y, Hideshima T, Podar K, Tai YT et al. Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications. Leukemia 2001; 15: 1950-1961.
46. Uchiyama H, Barut BA, Mohrbacher AF, Chauhan D, Anderson KC. Adhesion of human myeloma-derived cell lines to bone marrow stromal cells stimulates interleukin-6 secretion. Blood 1993; 82: 3712-3720.
47. Levesque JP, Winkler IG, Hendy J, Williams B, Helwani F, Barbier V et al. Hematopoietic progenitor cell mobilization results in hypoxia with increased hypoxia-inducible transcription factor-1 alpha and vascular endothelial growth factor A in bone marrow. Stem Cells 2007; 25: 1954-1965.
48. Eliasson P, Jonsson JI. The hematopoietic stem cell niche: low in oxygen but a nice place to be. J Cell Physiol 2010; 222: 17-22.
49. Kubota Y, Takubo K, Suda T. Bone marrow long label-retaining cells reside in the sinusoidal hypoxic niche. Biochem Biophys Res Commun 2008; 366: 335-339.
50. Martin SK, Diamond P, Gronthos S, Peet DJ, Zannettino AC. The emerging role of hypoxia, HIF-1 and HIF-2 in multiple myeloma. Leukemia 2011; 25: 1533-1542.
51. Asosingh K, De Raeve H, de Ridder M, Storme GA, Willems A, Van Riet I et al. Role of the hypoxic bone marrow microenvironment in 5T2MM murine myeloma tumor progression. Haematologica 2005; 90: 810-817.
52. Martin SK, Diamond P, Williams SA, To LB, Peet DJ, Fujii N et al. Hypoxia-inducible factor-2 is a novel regulator of aberrant CXCL12 expression in multiple myeloma plasma cells. Haematologica 2010; 95: 776-784.
53. Wright DE, Wagers AJ, Gulati AP, Johnson FL, Weissman IL. Physiological migration of hematopoietic stem and progenitor cells. Science 2001; 294: 1933-1936.
54. Nagasawa T. A chemokine, SDF-1/PBSF, and its receptor, CXC chemokine receptor 4, as mediators of hematopoiesis. Int J Hematol 2000; 72: 408-411.
55. Broxmeyer HE, Orschell CM, Clapp DW, Hangoc G, Cooper S, Plett PA et al. Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist. J Exp Med 2005; 201: 1307-1318.
56. Christopher MJ, Liu F, Hilton MJ, Long F, Link DC. Suppression of CXCL12 production by bone marrow osteoblasts is a common and critical pathway for cytokine-induced mobilization. Blood 2009; 114: 1331-1339.
57. Liles WC, Broxmeyer HE, Rodger E, Wood B, Hubel K, Cooper S et al. Mobilization of hematopoietic progenitor cells in healthy volunteers by AMD3100, a CXCR4 antagonist. Blood 2003; 102: 2728-2730.
58. Levesque JP, Hendy J, Takamatsu Y, Simmons PJ, Bendall LJ. Disruption of the CXCR4/CXCL12 chemotactic interaction during hematopoietic stem cell mobilization induced by GCSF or cyclophosphamide. J Clin Invest 2003; 111: 187-196.
59. Petit I, Szyper-Kravitz M, Nagler A, Lahav M, Peled A, Habler L et al. G-CSF induces stem cell mobilization by decreasing bone marrow SDF-1 and up-regulating CXCR4. Nat Immunol 2002; 3: 687-694.
60. Nie Y, Han YC, Zou YR. CXCR4 is required for the quiescence of primitive hematopoietic cells. J Exp Med 2008; 205: 777-783.
61. Alsayed Y, Ngo H, Runnels J, Leleu X, Singha UK, Pitsillides CM et al. Mechanisms of regulation of CXCR4/SDF-1 (CXCL12)-dependent migration and homing in multiple myeloma. Blood 2007; 109: 2708-2717.
62. Menu E, Asosingh K, Indraccolo S, De Raeve H, Van Riet I, Van Valckenborgh E et al. The involvement of stromal derived factor 1alpha in homing and progression of multiple myeloma in the 5TMM model. Haematologica 2006; 91: 605-612.
63. Gazitt Y, Akay C. Mobilization of myeloma cells involves SDF-1/CXCR4 signaling and downregulation of VLA-4. Stem Cells 2004; 22: 65-73.
64. Pellegrino A, Ria R, Di Pietro G, Cirulli T, Surico G, Pennisi A et al. Bone marrow endothelial cells in multiple myeloma secrete CXC-chemokines that mediate interactions with plasma cells. Br J Haematol 2005; 129: 248-256.
65. Martin SK, Dewar AL, Farrugia AN, Horvath N, Gronthos S, To LB et al. Tumor angiogenesis is associated with plasma levels of stromal-derived factor-1alpha in patients with multiple myeloma. Clin Cancer Res 2006; 12: 6973-6977.
66. Zannettino AC, Farrugia AN, Kortesidis A, Manavis J, To LB, Martin SK et al. Elevated serum levels of stromal-derived factor-1alpha are associated with increased osteoclast activity and osteolytic bone disease in multiple myeloma patients. Cancer Res 2005; 65: 1700-1709.
67. Kawano M, Hirano T, Matsuda T, Taga T, Horii Y, Iwato K et al. Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature 1988; 332: 83-85.
68. Klein B, Zhang XG, Jourdan M, Content J, Houssiau F, Aarden L et al. Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6. Blood 1989; 73: 517-526.
69. Arnulf B, Lecourt S, Soulier J, Ternaux B, Lacassagne MN, Crinquette A et al. Phenotypic and functional characterization of bone marrow mesenchymal stem cells derived from patients with multiple myeloma. Leukemia 2007; 21: 158-163.
70. Xu S, Menu E, Becker AD, Van Camp B, Vanderkerken K, Van Riet I. Bone marrow-derived mesenchymal stromal cells are attracted by multiple myeloma cell-produced chemokine CCL25 and favor myeloma cell growth in vitro and in vivo. Stem Cells 2012; 30: 266-279.
71. Daynes RA, Araneo BA, Ershler WB, Maloney C, Li GZ, Ryu SY. Altered regulation of IL-6 production with normal aging. Possible linkage to the age-associated decline in dehydroepiandrosterone and its sulfated derivative. J Immunol 1993; 150: 5219-5230.
72. Ershler WB, Keller ET. Age-associated increased interleukin-6 gene expression, late-life diseases, and frailty. Annu Rev Med 2000; 51: 245-270.
73. Jilka RL, Hangoc G, Girasole G, Passeri G, Williams DC, Abrams JS et al. Increased osteoclast development after estrogen loss: mediation by interleukin-6. Science 1992; 257: 88-91.
74. Miyaura C, Kusano K, Masuzawa T, Chaki O, Onoe Y, Aoyagi M et al. Endogenous bone-resorbing factors in estrogen deficiency: cooperative effects of IL-1 and IL-6. J Bone Miner Res 1995; 10: 1365-1373.
75. Bellido T, Jilka RL, Boyce BF, Girasole G, Broxmeyer H, Dalrymple SA et al. Regulation of interleukin-6, osteoclastogenesis, and bone mass by androgens. The role of the androgen receptor. J Clin Invest 1995; 95: 2886-2895.
76. Priestley GV, Scott LM, Ulyanova T, Papayannopoulou T. Lack of alpha4 integrin expression in stem cells restricts competitive function and self-renewal activity. Blood 2006; 107: 2959-2967.
77. Jiang Y, Bonig H, Ulyanova T, Chang K, Papayannopoulou T. On the adaptation of endosteal stem cell niche function in response to stress. Blood 2009; 114: 3773-3782.
78. Ulyanova T, Priestley GV, Nakamoto B, Jiang Y, Papayannopoulou T. VCAM-1 ablation in nonhematopoietic cells in MxCre VCAM-1 f/f mice is variable and dictates their phenotype. Exp Hematol 2007; 35: 565-571.
79. Cottler-Fox MH, Lapidot T, Petit I, Kollet O, DiPersio JF, Link D et al. Stem cell mobilization. Hematology Am Soc Hematol Educ Program 2003; 419-437.
80. Levesque JP, Takamatsu Y, Nilsson SK, Haylock DN, Simmons PJ. Vascular cell adhesion molecule-1 (CD106) is cleaved by neutrophil proteases in the bone marrow following hematopoietic progenitor cell mobilization by granulocyte colony-stimulating factor. Blood 2001; 98: 1289-1297.
81. Ramirez P, Rettig MP, Uy GL, Deych E, Holt MS, Ritchey JK et al. BIO5192, a small molecule inhibitor of VLA-4, mobilizes hematopoietic stem and progenitor cells. Blood 2009; 114: 1340-1343.
82. Holt RU, Baykov V, Ro TB, Brabrand S, Waage A, Sundan A et al. Human myeloma cells adhere to fibronectin in response to hepatocyte growth factor. Haematologica 2005; 90: 479-488.
83. Michigami T, Shimizu N, Williams PJ, Niewolna M, Dallas SL, Mundy GR et al. Cellcell contact between marrow stromal cells and myeloma cells via VCAM-1 and alpha(4)beta(1)-integrin enhances production of osteoclast-stimulating activity. Blood 2000; 96: 1953-1960.
84. Olson DL, Burkly LC, Leone DR, Dolinski BM, Lobb RR. Anti-alpha4 integrin monoclonal antibody inhibits multiple myeloma growth in a murine model. Mol Cancer Ther 2005; 4: 91-99.
85. Giatromanolaki A, Bai M, Margaritis D, Bourantas KL, Koukourakis MI, Sivridis E et al. Hypoxia and activated VEGF/receptor pathway in multiple myeloma. Anticancer Res 2010; 30: 2831-2836.
86. Gerber HP, Malik AK, Solar GP, Sherman D, Liang XH, Meng G et al. VEGF regulates haematopoietic stem cell survival by an internal autocrine loop mechanism. Nature 2002; 417: 954-958.
87. Colla S, Morandi F, Lazzaretti M, Polistena P, Svaldi M, Coser P et al. Do human myeloma cells directly produce basic FGF? Blood 2003; 102: author reply 3072-3073.
88. Kumar S, Witzig TE, Timm M, Haug J, Wellik L, Fonseca R et al. Expression of VEGF and its receptors by myeloma cells. Leukemia 2003; 17: 2025-2031.
89. Podar K, Tai YT, Davies FE, Lentzsch S, Sattler M, Hideshima T et al. Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration. Blood 2001; 98: 428-435.
90. Vacca A, Ria R, Ribatti D, Semeraro F, Djonov V, Di Raimondo F et al. A paracrine loop in the vascular endothelial growth factor pathway triggers tumor angiogenesis and growth in multiple myeloma. Haematologica 2003; 88: 176-185.
91. Dankbar B, Padro T, Leo R, Feldmann B, Kropff M, Mesters RM et al. Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma. Blood 2000; 95: 2630-2636.
92. Arai F, Hirao A, Ohmura M, Sato H, Matsuoka S, Takubo K et al. Tie2/angiopoietin- 1 signaling regulates hematopoietic stem cell quiescence in the bone marrow niche. Cell 2004; 118: 149-161.
93. Hsu HC, Ema H, Osawa M, Nakamura Y, Suda T, Nakauchi H. Hematopoietic stem cells express Tie-2 receptor in the murine fetal liver. Blood 2000; 96: 3757-3762.
94. Mayack SR, Wagers AJ. Osteolineage niche cells initiate hematopoietic stem cell mobilization. Blood 2008; 112: 519-531.
95. Nilsson SK, Johnston HM, Whitty GA, Williams B, Webb RJ, Denhardt DT et al. Osteopontin, a key component of the hematopoietic stem cell niche and regulator of primitive hematopoietic progenitor cells. Blood 2005; 106: 1232-1239.
96. Stier S, Ko Y, Forkert R, Lutz C, Neuhaus T, Grunewald E et al. Osteopontin is a hematopoietic stem cell niche component that negatively regulates stem cell pool size. J Exp Med 2005; 201: 1781-1791.
97. Morisada T, Kubota Y, Urano T, Suda T, Oike Y. Angiopoietins and angiopoietinlike proteins in angiogenesis. Endothelium 2006; 13: 71-79.
98. Reiss Y. Angiopoietins. Recent Results Cancer Res 2010; 180: 3-13.
99. Sato TN, Qin Y, Kozak CA, Audus KL. Tie-1 and tie-2 define another class of putative receptor tyrosine kinase genes expressed in early embryonic vascular system. Proc Nat Acad Sci USA 1993; 90: 9355-9358.
100. Suri C, Jones PF, Patan S, Bartunkova S, Maisonpierre PC, Davis S et al. Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell 1996; 87: 1171-1180.
101. Suri C, McClain J, Thurston G, McDonald DM, Zhou H, Oldmixon EH et al. Increased vascularization in mice overexpressing angiopoietin-1. Science 1998; 282: 468-471.
102. Giuliani N, Colla S, Lazzaretti M, Sala R, Roti G, Mancini C et al. Proangiogenic properties of human myeloma cells: production of angiopoietin-1 and its potential relationship to myeloma-induced angiogenesis. Blood 2003; 102: 638-645.
103. Tanaka Y, Abe M, Hiasa M, Oda A, Amou H, Nakano A et al. Myeloma cellosteoclast interaction enhances angiogenesis together with bone resorption: a role for vascular endothelial cell growth factor and osteopontin. Clin Cancer Res 2007; 13: 816-823.
104. Abe M, Hiura K, Wilde J, Shioyasono A, Moriyama K, Hashimoto T et al. Osteoclasts enhance myeloma cell growth and survival via cell-cell contact: a vicious cycle between bone destruction and myeloma expansion. Blood 2004; 104: 2484-2491.
105. Asou Y, Rittling SR, Yoshitake H, Tsuji K, Shinomiya K, Nifuji A et al. Osteopontin facilitates angiogenesis, accumulation of osteoclasts, and resorption in ectopic bone. Endocrinology 2001; 142: 1325-1332.
106. Nakamura Y, Arai F, Iwasaki H, Hosokawa K, Kobayashi I, Gomei Y et al. Isolation and characterization of endosteal niche cell populations that regulate hematopoietic stem cells. Blood 2010; 116: 1422-1432.
107. Todoerti K, Lisignoli G, Storti P, Agnelli L, Novara F, Manferdini C et al. Distinct transcriptional profiles characterize bone microenvironment mesenchymal cells rather than osteoblasts in relationship with multiple myeloma bone disease. Exp Hematol 2010; 38: 141-153.
108. Corre J, Mahtouk K, Attal M, Gadelorge M, Huynh A, Fleury-Cappellesso S et al. Bone marrow mesenchymal stem cells are abnormal in multiple myeloma. Leukemia 2007; 21: 1079-1088.
109. Wang X, Zhang Z, Yao C. Angiogenic activity of mesenchymal stem cells in multiple myeloma. Cancer Invest 2011; 29: 37-41.
110. Gregoretti MG, Gottardi D, Ghia P, Bergui L, Merico F, Marchisio PC et al. Characterization of bone marrow stromal cells from multiple myeloma. Leuk Res 1994; 18: 675-682.
111. Garderet L, Mazurier C, Chapel A, Ernou I, Boutin L, Holy X et al. Mesenchymal stem cell abnormalities in patients with multiple myeloma. Leuk Lymphoma 2007; 48: 2032-2041.
112. Jones EA, English A, Kinsey SE, Straszynski L, Emery P, Ponchel F et al. Optimization of a flow cytometry-based protocol for detection and phenotypic characterization of multipotent mesenchymal stromal cells from human bone marrow. Cytometry B Clin Cytom 2006; 70: 391-399.
113. Psaltis PJ, Paton S, See F, Arthur A, Martin S, Itescu S et al. Enrichment for STRO-1 expression enhances the cardiovascular paracrine activity of human bone marrow-derived mesenchymal cell populations. J Cell Physiol 2010; 223: 530-540.
114. Dawson MR, Chae SS, Jain RK, Duda DG. Direct evidence for lineage-dependent effects of bone marrow stromal cells on tumor progression. Am J Cancer Res 2011; 1: 144-154.
115. Ducy P, Zhang R, Geoffroy V, Ridall AL, Karsenty G. Osf2/Cbfa1: a transcriptional activator of osteoblast differentiation. Cell 1997; 89: 747-754.
116. Franceschi RT, Xiao G, Jiang D, Gopalakrishnan R, Yang S, Reith E. Multiple signaling pathways converge on the Cbfa1/Runx2 transcription factor to regulate osteoblast differentiation. Connect Tissue Res 2003; 44(Suppl 1): 109-116.
117. Karsenty G, Ducy P, Starbuck M, Priemel M, Shen J, Geoffroy V et al. Cbfa1 as a regulator of osteoblast differentiation and function. Bone 1999; 25: 107-108.
118. Hu H, Hilton MJ, Tu X, Yu K, Ornitz DM, Long F. Sequential roles of Hedgehog and Wnt signaling in osteoblast development. Development 2005; 132: 49-60.
119. Alfaro MP, Vincent A, Saraswati S, Thorne CA, Hong CC, Lee E et al. sFRP2 suppression of bone morphogenic protein (BMP) and Wnt signaling mediates mesenchymal stem cell (MSC) self-renewal promoting engraftment and myocardial repair. J Biol Chem 2010; 285: 35645-35653.
120. Oshima T, Abe M, Asano J, Hara T, Kitazoe K, Sekimoto E et al. Myeloma cells suppress bone formation by secreting a soluble Wnt inhibitor, sFRP-2. Blood 2005; 106: 3160-3165.
121. Qiang YW, Barlogie B, Rudikoff S, Shaughnessy Jr JD . Dkk1-induced inhibition of Wnt signaling in osteoblast differentiation is an underlying mechanism of bone loss in multiple myeloma. Bone 2008; 42: 669-680.
122. Tian E, Zhan F, Walker R, Rasmussen E, Ma Y, Barlogie B et al. The role of the Wntsignaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med 2003; 349: 2483-2494.
123. Canalis E. Notch signaling in osteoblasts. Sci Signal 2008; 1: pe17.
124. Deregowski V, Gazzerro E, Priest L, Rydziel S, Canalis E. Notch 1 overexpression inhibits osteoblastogenesis by suppressing Wnt/beta-catenin but not bone morphogenetic protein signaling. J Biol Chem 2006; 281: 6203-6210.
125. Hilton MJ, Tu X, Wu X, Bai S, Zhao H, Kobayashi T et al. Notch signaling maintains bone marrow mesenchymal progenitors by suppressing osteoblast differentiation. Nat Med 2008; 14: 306-314.
126. Plaisant M, Fontaine C, Cousin W, Rochet N, Dani C, Peraldi P. Activation of hedgehog signaling inhibits osteoblast differentiation of human mesenchymal stem cells. Stem Cells 2009; 27: 703-713.
127. Adams GB, Scadden DT. The hematopoietic stem cell in its place. Nat Immunol 2006; 7: 333-337.
128. Ehninger A, Trumpp A. The bone marrow stem cell niche grows up: mesenchymal stem cells and macrophages move in. J Exp Med 2011; 208: 421-428.
129. Qian H, Buza-Vidas N, Hyland CD, Jensen CT, Antonchuk J, Mansson R et al. Critical role of thrombopoietin in maintaining adult quiescent hematopoietic stem cells. Cell Stem Cell 2007; 1: 671-684.
130. Winkler IG, Sims NA, Pettit AR, Barbier V, Nowlan B, Helwani F et al. Bone marrow macrophages maintain hematopoietic stem cell (HSC) niches and their depletion mobilizes HSCs. Blood 2010; 116: 4815-4828.
131. Yoshihara H, Arai F, Hosokawa K, Hagiwara T, Takubo K, Nakamura Y et al. Thrombopoietin/MPL signaling regulates hematopoietic stem cell quiescence and interaction with the osteoblastic niche. Cell Stem Cell 2007; 1: 685-697.
132. Visnjic D, Kalajzic Z, Rowe DW, Katavic V, Lorenzo J, Aguila HL. Hematopoiesis is severely altered in mice with an induced osteoblast deficiency. Blood 2004; 103: 3258-3264.
133. Raaijmakers MH, Mukherjee S, Guo S, Zhang S, Kobayashi T, Schoonmaker JA et al. Bone progenitor dysfunction induces myelodysplasia and secondary leukaemia. Nature 2010; 464: 852-857.
134. Giuliani N, Colla S, Morandi F, Lazzaretti M, Sala R, Bonomini S et al. Myeloma cells block RUNX2/CBFA1 activity in human bone marrow osteoblast progenitors and inhibit osteoblast formation and differentiation. Blood 2005; 106: 2472-2483.
135. Silvestris F, Cafforio P, Calvani N, Dammacco F. Impaired osteoblastogenesis in myeloma bone disease: role of upregulated apoptosis by cytokines and malignant plasma cells. Br J Haematol 2004; 126: 475-486.
136. Silvestris F, Cafforio P, Tucci M, Grinello D, Dammacco F. Upregulation of osteoblast apoptosis by malignant plasma cells: a role in myeloma bone disease. Br J Haematol 2003; 122: 39-52.
137. Farrugia AN, Atkins GJ, To LB, Pan B, Horvath N, Kostakis P et al. Receptor activator of nuclear factor-kappaB ligand expression by human myeloma cells mediates osteoclast formation in vitro and correlates with bone destruction in vivo. Cancer Res 2003; 63: 5438-5445.
138. Yaccoby S, Wezeman MJ, Henderson A, Cottler-Fox M, Yi Q, Barlogie B et al. Cancer and the microenvironment: myeloma-osteoclast interactions as a model. Cancer Res 2004; 64: 2016-2023.
139. Yaccoby S, Wezeman MJ, Zangari M, Walker R, Cottler-Fox M, Gaddy D et al. Inhibitory effects of osteoblasts and increased bone formation on myeloma in novel culture systems and a myelomatous mouse model. Haematologica 2006; 91: 192-199.
140. Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998; 93: 165-176.
141. Giuliani N, Bataille R, Mancini C, Lazzaretti M, Barille S. Myeloma cells induce imbalance in the osteoprotegerin/osteoprotegerin ligand system in the human bone marrow environment. Blood 2001; 98: 3527-3533.
142. Pearse RN, Sordillo EM, Yaccoby S, Wong BR, Liau DF, Colman N et al. Multiple myeloma disrupts the TRANCE/ osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression. Proc Nat Acad Sci USA 2001; 98: 11581-11586.
143. Seidel C, Hjertner O, Abildgaard N, Heickendorff L, Hjorth M, Westin J et al. Serum osteoprotegerin levels are reduced in patients with multiple myeloma with lytic bone disease. Blood 2001; 98: 2269-2271.
144. Kurihara N, Bertolini D, Suda T, Akiyama Y, Roodman GD. IL-6 stimulates osteoclast-like multinucleated cell formation in long term human marrow cultures by inducing IL-1 release. J Immunol 1990; 144: 4226-4230.
145. Tamura T, Udagawa N, Takahashi N, Miyaura C, Tanaka S, Yamada Y et al. Soluble interleukin-6 receptor triggers osteoclast formation by interleukin 6. Proc Nat Acad Sci USA 1993; 90: 11924-11928.
146. Diamond P, Labrinidis A, Martin SK, Farrugia AN, Gronthos S, To LB et al. Targeted disruption of the CXCL12/CXCR4 axis inhibits osteolysis in a murine model of myeloma-associated bone loss. J Bone Miner Res 2009; 24: 1150-1161.
147. Fleming HE, Janzen V, Lo Celso C, Guo J, Leahy KM, Kronenberg HM et al. Wnt signaling in the niche enforces hematopoietic stem cell quiescence and is necessary to preserve self-renewal in vivo. Cell Stem Cell 2008; 2: 274-283.
148. Schaniel C, Sirabella D, Qiu J, Niu X, Lemischka IR, Moore KA. Wnt-inhibitory factor 1 dysregulation of the bone marrow niche exhausts hematopoietic stem cells. Blood 2011; 118: 2420-2429.
149. Yaccoby S, Ling W, Zhan F, Walker R, Barlogie B, Shaughnessy Jr. JD . Antibodybased inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo. Blood 2007; 109: 2106-2111.
150. Chim CS, Pang R, Fung TK, Choi CL, Liang R. Epigenetic dysregulation of Wnt signaling pathway in multiple myeloma. Leukemia 2007; 21: 2527-2536.
151. Derksen PW, Tjin E, Meijer HP, Klok MD, MacGillavry HD, van Oers MH et al. Illegitimate WNT signaling promotes proliferation of multiple myeloma cells. Proc Nat Acad Sci USA 2004; 101: 6122-6127.
152. Edwards CM, Edwards JR, Lwin ST, Esparza J, Oyajobi BO, McCluskey B et al. Increasing Wnt signaling in the bone marrow microenvironment inhibits the development of myeloma bone disease and reduces tumor burden in bone in vivo. Blood 2008; 111: 2833-2842.
153. Duncan AW, Rattis FM, DiMascio LN, Congdon KL, Pazianos G, Zhao C et al. Integration of Notch and Wnt signaling in hematopoietic stem cell maintenance. Nat Immunol 2005; 6: 314-322.
154. Suzuki T, Chiba S. Notch signaling in hematopoietic stem cells. Int J Hematol 2005; 82: 285-294.
155. Varnum-Finney B, Xu L, Brashem-Stein C, Nourigat C, Flowers D, Bakkour S et al. Pluripotent, cytokine-dependent, hematopoietic stem cells are immortalized by constitutive Notch1 signaling. Nat Med 2000; 6: 1278-1281.
156. Houde C, Li Y, Song L, Barton K, Zhang Q, Godwin J et al. Overexpression of the NOTCH ligand JAG2 in malignant plasma cells from multiple myeloma patients and cell lines. Blood 2004; 104: 3697-3704.
157. Merchant AA, Matsui W. Targeting Hedgehog-a cancer stem cell pathway. Clin Cancer Res 2010; 16: 3130-3140.
158. Taipale J, Beachy PA. The Hedgehog and Wnt signalling pathways in cancer. Nature 2001; 411: 349-354.
159. Gao J, Graves S, Koch U, Liu S, Jankovic V, Buonamici S et al. Hedgehog signaling is dispensable for adult hematopoietic stem cell function. Cell Stem Cell 2009; 4: 548-558.
160. Hamburger A, Salmon SE. Primary bioassay of human myeloma stem cells. J Clin Invest 1977; 60: 846-854.
161. Park CH, Bergsagel DE, McCulloch EA. Mouse myeloma tumor stem cells: a primary cell culture assay. J Natl Cancer Inst 1971; 46: 411-422.
162. Pilarski LM, Belch AR. Clonotypic myeloma cells able to xenograft myeloma to nonobese diabetic severe combined immunodeficient mice copurify with CD34 () hematopoietic progenitors. Clin Cancer Res 2002; 8: 3198-3204.
163. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature 2001; 414: 105-111.
164. Peacock CD, Wang Q, Gesell GS, Corcoran-Schwartz IM, Jones E, Kim J et al. Hedgehog signaling maintains a tumor stem cell compartment in multiple myeloma. Proc Nat Acad Sci USA 2007; 104: 4048-4053.
165. Gunn WG, Krause U, Lee N, Gregory CA. Pharmaceutical inhibition of glycogen synthetase kinase-3beta reduces multiple myeloma-induced bone disease in a novel murine plasmacytoma xenograft model. Blood 2011; 117: 1641-1651.